DESCRIPTION OF SHARE CAPITALShare Capital Description • April 3rd, 2020 • Ascendis Pharma a/S • Pharmaceutical preparations
Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our articles of association, the registration rights agreement entered into in December 2014 to which we and certain shareholders are parties, as amended, or the 2014 Registration Rights Agreement, the registration rights agreement entered into in December 2015 to which we and certain holders of American Depositary Shares, also referred to as ADSs, are parties or the 2015 Registration Rights Agreement, and relevant provisions of the Danish Companies Act (in Danish: Selskabsloven). Because the following is only a summary, it does not contain all of the information that may be important to you. The summary includes certain references to and descriptions of material provisions of our articles of association, the 2014 Registration Rights Agreement, the 2015 Registration Rights Agreement and Danish law in effect as of the date of our Annual Report on Form 20-F.
PACKAGING AND SUPPLY AGREEMENTPackaging and Supply Agreement • April 3rd, 2020 • Ascendis Pharma a/S • Pharmaceutical preparations
This Packaging and Supply Agreement (the “Agreement”) effective as of December 1, 2019 (the “Effective Date”), is entered into by and between Sharp Corporation, a corporation organized and existing under the laws of Pennsylvania having its principal office at 7451 Keebler Way, Allentown, Pennsylvania 18106 (“Sharp”) and Ascendis Pharma A/S, a corporation organized and existing under the laws of Denmark having its principal office at Tuborg Boulevard 12, 2900 Hellerup, Denmark (“Ascendis”) (hereinafter individually referred to as “Party” and collectively as “the Parties”).
ContractTech Transfer and Manufacturing Services Agreement • April 3rd, 2020 • Ascendis Pharma a/S • Pharmaceutical preparations
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
